Detalhe da pesquisa
1.
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors.
Invest New Drugs
; 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38483782
2.
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.
Invest New Drugs
; 41(3): 380-390, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37040046
3.
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
Invest New Drugs
; 39(6): 1587-1597, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34180037
4.
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia.
Invest New Drugs
; 38(5): 1430-1441, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32020437
5.
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors.
Invest New Drugs
; 38(4): 1156-1165, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31734832
6.
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy.
J Exp Med
; 204(4): 831-40, 2007 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-17389240
7.
Prussian blue nanoparticles as nanocargoes for delivering DNA drugs to cancer cells.
Sci Technol Adv Mater
; 14(4): 044405, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27877590
8.
A novel DNA selection and direct extraction process and its application in DNA recombination.
Electrophoresis
; 32(3-4): 423-30, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21298668
9.
Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.
Haematologica
; 101(5): e185-8, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26869629
10.
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b studyâ.
Leuk Res
; 100: 106489, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33302031
11.
MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia.
Br J Haematol
; 171(3): 432-5, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25855517
12.
Enhancement of aptamer microarray sensitivity through spacer optimization and avidity effect.
Anal Chem
; 81(5): 1747-54, 2009 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19193102
13.
A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [14C]-labeled idasanutlin and an intravenous tracer dose of [13C]-labeled idasanutlin in a single cohort of patients with solid tumors.
Cancer Chemother Pharmacol
; 84(1): 93-103, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31062077
14.
Spectral contrast imaging method for mapping transmission surface plasmon images in metallic nanostructures.
Biosens Bioelectron
; 142: 111545, 2019 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31376712
15.
Confocal epifluorescence sensor with an arc-shaped aperture for slide-based PCR quantification.
Biosens Bioelectron
; 100: 71-78, 2018 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28863326
16.
Selection of aptamers for AMACR detection from DNA libraries with different primers.
RSC Adv
; 8(34): 19067-19074, 2018 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35539643
17.
Phase 1 summary of plasma concentration-QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML.
Cancer Chemother Pharmacol
; 81(3): 597-607, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29392451
18.
Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 81(3): 529-537, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29368050
19.
Signal-on Protein Detection via Dye Translocation between Aptamer and Quantum Dot.
ACS Appl Mater Interfaces
; 8(19): 12048-55, 2016 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-27101438
20.
A selective decoy-doxorubicin complex for targeted co-delivery, STAT3 probing and synergistic anti-cancer effect.
Chem Commun (Camb)
; 51(68): 13309-12, 2015 Sep 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-26207858